January 2005
The year 2004 ended with the US Food and Drug Administration (FDA) approval of new agents for macular degeneration, overactive bladder, pain management, pediatric leukemia, and mucositis. The approval of these very novel agents fills a void where there is no currently approved therapy or alternatives for some patients and diseases.

This month's column reviews FDA new product approvals and labeling changes for:

Analgesic Agents

Prialt (ziconotide) Intrathecal Injection

Antineoplastic Agents

Clolar (clofarabine) Injection

Anti-Ulcer Agents and Acid Suppressants

Nexium (esomeprazole) Capsules

Chemoprotectant Agents

Kepivance (palifermin) Injection

Genitourinary Agents

Enablex (darifenacin) Extended-Release Tablets

Ophthalmic Agents

Macugen (pegaptinib) Injection Vision Blue (trypan blue) Ophthalmic Solution